Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.
What happened
FDA inspected Nipro's Lewisberry, PA facility from February 2, 2026 through March 27, 2026. FDA found that the firm released and distributed hemodialysis products with endotoxin (a bacterial toxin) above specification even though lab reports marked the tests as passed, and that many endotoxin failures had no documented investigation. FDA also found missing design/development records, an uncalibrated sole endotoxin-testing instrument, leaking pipes without repair records, and missing UDI labeling on Dry complete dry acid concentrate.
What FDA found
FDA says the firm released and distributed hemodialysis products with endotoxin above the limit while lab forms incorrectly showed 'Passed,' and many endotoxin failures had no documented investigation.
ISO 13485:2016 Clause 8.3.1FDA says corrective actions were late, not scaled to the problems, and failed to prevent repeat failures, including an endotoxin release after a prior CAPA.
ISO 13485:2016 Clause 8.5.2FDA says the firm lacked design and development files for six marketed devices and made design changes, including endotoxin limit changes, without required records or impact assessments.
ISO 13485:2016 Clauses 7.3.1, 7.3.9FDA says the only instrument used for endotoxin testing had never been calibrated and was not validated for all liquid product lines or the out-of-specification retest procedure.
ISO 13485:2016 Clauses 7.6, 7.5.6FDA says pipes in the production system leaked and the firm had no repair records or impact assessment, and the endotoxin instrument had no maintenance records.
ISO 13485:2016 Clause 6.3FDA says labels for Nipro Dry complete dry acid concentrate lacked a unique device identifier (UDI), and required UDI data was not submitted to FDA's database.
21 CFR 801.20(a); 21 CFR 830.300(a), 830.320(b)
What FDA wants
FDA asks Nipro to provide planned actions for the released lots with endotoxin above specification and documentation or timeframes for all outstanding corrective actions, including verification that they worked; the excerpt does not state a response deadline.
Who should pay attention
- dialysis clinics and patients using these concentrates
- contract manufacturers of hemodialysis fluids
- quality teams that rely on one endotoxin-testing instrument
This is a summary. Read the original letter on fda.gov.